NASDAQ:IRD Opus Genetics Q2 2026 Earnings Report $3.52 -0.05 (-1.26%) As of 03:01 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Opus Genetics EPS ResultsActual EPSN/AConsensus EPS -$0.15Beat/MissN/AOne Year Ago EPSN/AOpus Genetics Revenue ResultsActual RevenueN/AExpected Revenue$2.64 millionBeat/MissN/AYoY Revenue GrowthN/AOpus Genetics Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time12:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Opus Genetics Earnings HeadlinesCantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)July 11, 2026 | theglobeandmail.comOpus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 ResultsJuly 9, 2026 | globenewswire.comConfirm Your Name Before the Letter Goes OutAmericans who believe in real retirement protection are adding their names to a statement going out to Washington and Wall Street. It's a message that people are fed up with inflation and the erosion of their savings. President Trump took a stand on protecting American wealth. Now you can add your voice while also learning how to move part of your IRA or 401(k) into physical gold and silver, tax and penalty free.July 15 at 1:00 AM | American Alternative (Ad)Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Opus Genetics (IRD) and Vertex Pharmaceuticals (VRTX)July 8, 2026 | theglobeandmail.comOpus Genetics' (IRD) "Buy" Rating Reaffirmed at BTIG ResearchJuly 7, 2026 | americanbankingnews.comOpus Genetics' (IRD) "Buy" Rating Reaffirmed at Chardan CapitalJuly 7, 2026 | americanbankingnews.comSee More Opus Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email. Email Address About Opus GeneticsOpus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.View Opus Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Johnson & Johnson’s Earnings Dip Looks Like a Buying OpportunityApple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before EarningsWhy ASML’s AI Monopoly Is Still Getting StrongerAlphabet’s AI Spending Question Looms Over Q2 EarningsCPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive StocksPlot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-MergerMarriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Upcoming Earnings GE Aerospace (7/16/2026)Taiwan Semiconductor Manufacturing (7/16/2026)Netflix (7/16/2026)Prologis (7/16/2026)State Street (7/16/2026)U.S. Bancorp (7/16/2026)Abbott Laboratories (7/16/2026)Intuitive Surgical (7/16/2026)UnitedHealth Group (7/16/2026)Fifth Third Bancorp (7/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
